Trust Signals
Written by the FormBlends Medical Team. Instructions align with the current Novo Nordisk Ozempic (semaglutide) U.S. Prescribing Information and patient Instructions for Use (IFU). Reviewed against FDA-approved labeling. No affiliate relationship with Novo Nordisk. Last updated: May 29, 2026.
Key Takeaways
- Priming is required only on first use of each pen; you attach a new needle and complete a needle-preparation step for subsequent injections with the same pen.
- The flow check symbol (two curved arrows) is the specific dial setting used during priming. Dialing to any numeric dose and pressing is not a valid prime.
- If no drop appears after pressing at the flow check symbol, Novo Nordisk instructs repeating up to 6 times before discarding the pen.
- Cold solution (straight from the refrigerator) increases viscosity and reduces dose accuracy. Allow 30 minutes at room temperature before priming or injecting.
- An unprimed injection can deliver a small subcutaneous air pocket and a measurably lower semaglutide dose than prescribed.
Direct Answer: How to Prime an Ozempic Pen
Attach a new needle, dial the selector to the flow check symbol, hold the pen needle-up, tap the cartridge to move bubbles upward, then press and hold the dose button until a drop of clear solution appears at the needle tip. The counter should return to the flow check symbol confirming a successful prime. This takes under 60 seconds.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What are the exact steps to prime an Ozempic pen?
- Do you have to prime the pen before every injection?
- What does the flow check symbol mean and where is it?
- What if no drop appears when you prime?
- Why does the Ozempic pen need to be primed at all?
- Why does temperature matter before priming?
- Evidence ledger: what the clinical data actually tells us
- What most instruction pages get wrong about priming
- How does Ozempic pen priming compare to other GLP-1 pens?
- How to read the pen and needle labels yourself
- FAQ
- Sources
What Are the Exact Steps to Prime an Ozempic Pen?
These steps follow the Novo Nordisk Ozempic Instructions for Use. Complete this sequence only on the very first injection from a new pen.
Do You Have to Prime the Pen Before Every Injection?
No. According to the Novo Nordisk Instructions for Use, the full flow-check prime is required only when using a pen for the first time. For every subsequent injection from the same pen, you attach a fresh needle and do a "needle preparation" check: dial to the flow check symbol, press until a drop appears, then dial to your dose. Some versions of the IFU label this simply as checking for flow rather than calling it a prime. The key distinction is this: you always verify flow with each new needle attachment, but you do not need to drain the same volume as an initial prime each time.
Attaching a needle and immediately injecting without any flow check risks delivering an air plug from inside the needle hub directly into your tissue.
What Does the Flow Check Symbol Mean and Where Is It?
The flow check symbol on Ozempic pens is two curved arrows forming a loop, resembling a recycling icon. It occupies the position on the dose counter just beyond the last available dose. On a 0.25 mg starter pen it appears after the 0.5 mg marking; on a 1 mg maintenance pen it appears after 1 mg.
This symbol specifically instructs the pen mechanism to deliver the minimum volume needed to fill the needle dead space and confirm that the plunger, cartridge seal, and fluid path are all functioning. It is not a partial dose. Dialing to a numeric dose and pressing instead of using the flow check symbol may expel semaglutide from your prescribed dose allotment rather than from the prime-reserved volume.
What If No Drop Appears When You Prime?
The Novo Nordisk IFU states: if no drop appears, repeat the priming check up to 6 times. Reasons a drop may not appear on the first press include:
- The needle was not attached tightly enough, creating a path for air to re-enter.
- A large air bubble is occupying the cartridge tip and needs multiple presses to fully clear.
- The pen was stored with the needle down, allowing solution to drain away from the tip.
- The pen is defective or, in rare cases, the cartridge is empty (which can happen with a pen that was previously used and not tracked).
If no drop appears after 6 attempts: do not inject with that pen. Replace the needle and use a new pen. Contact your pharmacist or Novo Nordisk customer support (1-833-NOVO-411 in the U.S.). Do not try to force delivery by pressing harder; the pen mechanism is designed with a specific pressure range.
Why Does the Ozempic Pen Need to Be Primed at All?
The Ozempic pen uses a pre-filled glass cartridge connected to a needle via a rubber-tipped tip connector. When a pen ships from the factory or sits in the refrigerator between uses, a small air gap can form between the solution and the needle hub. This happens because:
Thermal contraction. Liquid volume decreases slightly when cooled. A cartridge filled at room temperature and then stored at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit, per labeling) will have its solution contract, drawing a micro air pocket into the fluid column at the front of the cartridge.
Needle dead space. The inner volume of a 32G 4 mm needle is small but not zero. That space must be filled with solution before any meaningful dose exits the tip.
Priming physically displaces the air and fills the dead space with solution, ensuring that the first press of the dose button delivers semaglutide rather than air. A subcutaneous air injection is not acutely dangerous, but it does reduce the amount of drug actually delivered to tissue on that injection cycle.
Why Does Temperature Matter Before Priming?
Ozempic solution is stored refrigerated at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and, once in use, can be kept at room temperature (up to 30 degrees Celsius, 86 degrees Fahrenheit) for up to 56 days per FDA-approved labeling.
The relevant chemistry: semaglutide is formulated in a slightly viscous aqueous solution. Viscosity of aqueous solutions increases as temperature drops. A cold solution moving through a 32 gauge bore (inner diameter roughly 0.10 mm to 0.13 mm depending on needle manufacturer) encounters meaningfully more resistance than the same solution at 20 to 25 degrees Celsius. Higher resistance means the pen's spring-driven plunger may deliver a fractionally lower volume per press, particularly during the priming step where volumes are small. In practice, Novo Nordisk recommends removing the pen from the refrigerator and letting it reach room temperature for 30 minutes before injecting. This is a practical recommendation, not a strict pharmacological requirement, but it supports dose accuracy and reduces injection site stinging, which is partly a temperature effect on local tissue receptors.
Do not warm the pen with hot water, a heating pad, or direct sunlight. Semaglutide is a GLP-1 analogue with a fatty acid side chain that provides its albumin-binding half-life extension. Elevated temperatures above 30 degrees Celsius over time can accelerate degradation of the peptide backbone and the fatty acid linkage, reducing potency before the labeled 56-day in-use period ends. There is no color change or visible sign of heat-degraded semaglutide, which is why the storage rule matters operationally.
Evidence Ledger: What the Clinical Data Actually Tells Us
| Claim | Best evidence type | Effect direction | Confidence | Caveat |
|---|---|---|---|---|
| Subcutaneous semaglutide 0.25 to 1 mg weekly reduces HbA1c and body weight | Multiple phase 3 human RCTs (SUSTAIN program, Ozempic FDA NDA) | Strong reduction | High | These trials used correct pen technique; dose accuracy was assumed, not separately tested |
| Air bolus in subcutaneous tissue reduces delivered drug dose | Device engineering and pharmacokinetic principle; no dedicated human RCT | Dose reduction | Moderate (mechanistically sound, not directly trialed) | The clinical magnitude of one skipped prime on semaglutide AUC has not been formally measured |
| Cold viscosity increases injection resistance in fine-gauge needles | Physical chemistry principle; confirmed in insulin pen engineering literature | Increased resistance | Moderate | Semaglutide-specific viscosity data at 2 to 8 degrees Celsius is not publicly available; insulin data used as analogue |
| Priming step required only at first use per IFU | FDA-approved Ozempic IFU, Novo Nordisk labeling | Clear instruction | High (regulatory label) | Some compounded semaglutide vials and pens have different priming requirements; this page covers branded Ozempic only |
| Needle reuse increases injection pain and clogging risk | Human observational studies in insulin-using populations | Increased adverse outcomes | Moderate | Direct semaglutide needle reuse data absent; extrapolated from insulin pen literature |
What Most Instruction Pages Get Wrong About Priming
Most pharmacy handouts and medspa blog posts describe priming as simply "pressing until you see a drop." Three things they consistently omit:
1. The flow check symbol is mandatory, not optional. If you dial to your numeric dose and press until a drop appears, you have just delivered a small amount of your dose into the air. The flow check symbol setting routes fluid through the prime pathway. Dialing to 0.25 mg and pressing for a drop is a dose-wasting prime, not a proper one. This distinction matters on a pen with a fixed number of doses, especially for the 0.5 mg and 1 mg pens where cartridge volume is not generous.
2. Priming a pen that has been stored needle-on is not the same as priming a fresh pen. Leaving a needle attached between injections allows semaglutide solution to wick into and dry in the needle bore. It also creates a capillary path for air re-entry into the cartridge during refrigerator storage. When you prime a pen that has sat needle-on overnight in the fridge, you may need more than one press at the flow check symbol to clear not just air but dried crystalline residue at the needle tip. The correct practice is to remove the needle immediately after each injection and replace with a fresh one before the next use, as stated in the Novo Nordisk IFU.
3. A drop and a stream are not identical outcomes. The IFU shows a small drop as the confirmation. A large stream suggests the button was pressed without adequate air clearance beforehand, or the needle was not pointing up and bubbles were not consolidated. A stream is not a failure, but it suggests more medication was expelled than necessary. Tapping the cartridge before pressing is not cosmetic: it consolidates micro-bubbles so the prime clears them in one press rather than requiring multiple large presses.
How Does Ozempic Pen Priming Compare to Other GLP-1 Pens?
| Pen | Drug | Prime required at first use? | Prime symbol or step | Max prime attempts before discard | Needle supplied? |
|---|---|---|---|---|---|
| Ozempic (Novo Nordisk) | Semaglutide 0.25, 0.5, 1 mg | Yes | Flow check symbol (two curved arrows) | 6 | Yes (NovoFine Plus 32G 4 mm) |
| Wegovy (Novo Nordisk) | Semaglutide 0.25 to 2.4 mg | Yes | Flow check symbol, same design as Ozempic | 6 | Yes |
| Trulicity (Eli Lilly) | Dulaglutide 0.75, 1.5, 3, 4.5 mg | No (single-dose autoinjector) | Not applicable; device is single-use prefilled | Not applicable | Integrated (no attachment needed) |
| Victoza (Novo Nordisk) | Liraglutide 0.6, 1.2, 1.8 mg | Yes | Flow check symbol, same platform as Ozempic | 6 | Yes |
| Byetta (AstraZeneca, discontinued in U.S.) | Exenatide 5, 10 mcg | Yes | Dial to prime mark, press | Varied by IFU version | Yes |
The Ozempic and Wegovy pens use the same FlexTouch-platform device design from Novo Nordisk. If you are familiar with Victoza or a Tresiba insulin pen, the Ozempic priming steps will feel identical. Trulicity autoinjectors require no priming at all, which is a usability advantage for patients who find pen attachment steps confusing. That convenience comes at the cost of dose-titration flexibility, since each Trulicity device is fixed at one dose.
How to Read the Pen and Needle Labels Yourself
Pen label: The Ozempic pen label states semaglutide concentration as 1.34 mg/mL (the same concentration across all dose variants). The total volume in the cartridge is 1.5 mL for the 0.25 mg and 0.5 mg pen (which holds enough for four 0.25 mg or two 0.5 mg doses plus prime volume) and 3 mL for the 1 mg pen (which holds enough for four 1 mg doses plus prime volume). If you see a pen labeled with a concentration other than 1.34 mg/mL, it is not a branded Ozempic pen.
Needle label: Compatible needles should state gauge (32G or 31G are appropriate), length (4 mm to 6 mm for most adults), and compatibility with "Novo Nordisk pens" or "NovoFine compatible." The outer packaging should list sterility assurance (ISO 11608 compliance is the relevant standard for pen needles). Do not use insulin syringes or needles from other pen platforms; the attachment thread diameter and push-on mechanism are not universal across all manufacturers.
Checking pen fill level: The Ozempic pen does not have a transparent window to see remaining solution. The dose counter is your indicator. When the counter can no longer be turned to your prescribed dose, the pen is empty. Do not attempt to inject beyond the last countable dose; the pen will not fire.
Expiry dates: Two dates appear on the pen box: a manufacturer expiry and an in-use expiry. Once opened and kept at room temperature (up to 30 degrees Celsius), the pen must be used within 56 days regardless of the manufacturer expiry. Write the date you open the pen on the label in permanent marker.
FAQ
Sources
- Novo Nordisk. Ozempic (semaglutide) Prescribing Information. U.S. FDA-approved labeling. Plainsboro, NJ: Novo Nordisk Inc. Current label accessible via FDA Drugs@FDA database.
- Novo Nordisk. Ozempic Pen Instructions for Use. Packaged with Ozempic 0.25 mg/0.5 mg and 1 mg pens. Current version distributed with U.S. dispensed product.
- U.S. Food and Drug Administration. Ozempic New Drug Application 209637. FDA Center for Drug Evaluation and Research. Available at fda.gov/drugs.
- Marso SP, Bain SC, Consoli A, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." New England Journal of Medicine. 2016;375(19):1834-1844. (SUSTAIN-6 trial)
- Aroda VR, Bain SC, Cariou B, et al. "Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin with or without sulfonylureas." Lancet Diabetes Endocrinol. 2017;5(5):355-366. (SUSTAIN-4)
- Kreider KE. "Pen Devices for Insulin Administration." Journal of Diabetes Science and Technology. 2020;14(3):560-567. General review of pen device mechanics including priming and dead space.
- ISO 11608-1:2022. Needle-based injection systems for medical use: Requirements and test methods. International Organization for Standardization.
- Frid AH, Hirsch LJ, Menchior AR, Morel DR, Strauss KW. "Worldwide Injection Technique Questionnaire Study." Mayo Clinic Proceedings. 2016;91(9):1224-1230. Evidence on needle reuse and injection outcomes in insulin-using populations.
Footer Disclaimers
Platform: FormBlends is an informational health publishing platform. This page does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Medication status: Ozempic (semaglutide) is an FDA-approved prescription medication indicated for type 2 diabetes management. It is not approved as a standalone weight-loss drug under the Ozempic brand; Wegovy (semaglutide) carries that indication. Use only as directed by your prescriber.
Results: Individual responses to semaglutide vary. Clinical trial outcomes represent group averages and do not guarantee any specific result for any individual patient.
Trademark: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. NovoFine is a registered trademark of Novo Nordisk A/S. FormBlends has no commercial affiliation with Novo Nordisk.